Prelude Therapeutics (PRLD) Capital Expenditures Growth (1y) (2020 - 2025)
Prelude Therapeutics (PRLD) Capital Expenditures Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | - |
| 10 | Prelude Therapeutics | 332.56 Mn | 187.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -94.43% |
| Mar 31, 2025 | -83.74% |
| Dec 31, 2024 | -162.09% |
| Sep 30, 2024 | -89.34% |
| Jun 30, 2024 | -63.48% |
| Mar 31, 2024 | -64.32% |
| Dec 31, 2023 | 584.55% |
| Sep 30, 2023 | 142.61% |
| Jun 30, 2023 | -27.51% |
| Mar 31, 2023 | 128.81% |
| Dec 31, 2022 | 80.90% |
| Sep 30, 2022 | -184.57% |
| Jun 30, 2022 | 326.00% |
| Mar 31, 2022 | -64.10% |
| Dec 31, 2021 | -357.93% |
| Sep 30, 2021 | 864.71% |
| Jun 30, 2021 | -774.16% |
| Mar 31, 2021 | 2,887.88% |
| Dec 31, 2020 | 1,226.19% |